SCFA Alterations in IBS Subtypes: Systematic Evidence and Future Prospects for Biomarker-Based Diagnosis in India.
- 1Department of Biosciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India.
- 2Department of Public Health, Dr. Vishwanath Karad MIT World Peace University, Pune, India.
Abstract
Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits. Short-chain fatty acids (SCFAs), microbial metabolites of dietary fiber, play key roles in gut physiology and have been implicated in IBS pathogenesis. Propionate, acetate, and butyrate are of particular interest as potential biomarkers for diagnosis and subtype differentiation. A systematic search of PubMed, Web of Science, and Embase identified studies reporting fecal SCFA concentrations in IBS patients versus healthy controls (HCs). Adult cohorts diagnosed by Rome criteria, case-control or randomized designs, and sufficient SCFA data for effect size calculation were included. Data were harmonized to mean ± SD and analyzed; pooled standardized mean differences (SMDs) with 95% confidence intervals (CI) were calculated, with subgroup analyses for IBS-D and IBS-C. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Eleven studies met inclusion criteria. Across all IBS cohorts, propionate was significantly elevated compared to HCs, while acetate and butyrate showed no differences. In IBS-D, propionate was consistently higher. In IBS-C, total SCFAs were significantly reduced, with negligible heterogeneity. Acetate, propionate, and butyrate remained non-significant, with moderate to substantial heterogeneity. NOS assessment indicated that most studies were of good quality, with one rated moderate. This meta-analysis highlights propionate elevation as a biomarker for IBS, particularly IBS-D, and reduced total SCFAs as a distinct metabolic signature in IBS-C. Variability in individual metabolites reflects dietary and methodological influences. The absence of Indian cohorts limits generalizability; future studies integrating SCFA profiling with microbiome analysis in Indian populations are needed to validate biomarker utility and support precision management of IBS.
Related
- ADAM10 as a Potential Biomarker in Non-Small Cell Lung Cancer and Its Major Histologic Subtypes
- Multi-omics profiling uncovers diagnostic biomarker panel, progression-associated subtypes, and prognostic signature in pediatric mitochondrial disease
- Editorial: Kidney cancer awareness month 2025: current progress and future prospects on kidney cancer prevention, diagnosis and treatment
- Alterations of Gastric Fluid Microbiota in Functional Dyspepsia and Its Subtypes Including Postprandial Distress Syndrome and Epigastric Pain Syndrome: A Pilot Study
- Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma
BibTeX
@article{limaye2026scfa,
title = {{SCFA Alterations in IBS Subtypes: Systematic Evidence and Future Prospects for Biomarker-Based Diagnosis in India.}},
author = {Sanika Limaye and Prajkta Bhide and Anup Kale and Neha Bokey},
journal = {Journal of microbiology and biotechnology},
year = {2026},
month = sep,
doi = {10.4014/jmb.2605.05029},
url = {https://europepmc.org/article/MED/42834635},
note = {CC BY},
}
RIS
TY - JOUR
TI - SCFA Alterations in IBS Subtypes: Systematic Evidence and Future Prospects for Biomarker-Based Diagnosis in India.
AU - Sanika Limaye
AU - Prajkta Bhide
AU - Anup Kale
AU - Neha Bokey
PY - 2026
DA - 2026/09/02
JO - Journal of microbiology and biotechnology
DO - 10.4014/jmb.2605.05029
UR - https://europepmc.org/article/MED/42834635
AB - Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits. Short-chain fatty acids (SCFAs), microbial metabolites of dietary fiber, play key roles in gut physiology and have been implicated in IBS pathogenesis. Propionate, acetate, and butyrate are of particular interest as potential biomarkers for diagnosis and subtype differentiation. A systematic search of PubMed, Web of Science, and Embase identified studies reporting fecal SCFA concentrations in IBS patients versus healthy controls (HCs). Adult cohorts diagnosed by Rome criteria, case-control or randomized designs, and sufficient SCFA data for effect size calculation were included. Data were harmonized to mean ± SD and analyzed; pooled standardized mean differences (SMDs) with 95% confidence intervals (CI) were calculated, with subgroup analyses for IBS-D and IBS-C. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Eleven studies met inclusion criteria. Across all IBS cohorts, propionate was significantly elevated compared to HCs, while acetate and butyrate showed no differences. In IBS-D, propionate was consistently higher. In IBS-C, total SCFAs were significantly reduced, with negligible heterogeneity. Acetate, propionate, and butyrate remained non-significant, with moderate to substantial heterogeneity. NOS assessment indicated that most studies were of good quality, with one rated moderate. This meta-analysis highlights propionate elevation as a biomarker for IBS, particularly IBS-D, and reduced total SCFAs as a distinct metabolic signature in IBS-C. Variability in individual metabolites reflects dietary and methodological influences. The absence of Indian cohorts limits generalizability; future studies integrating SCFA profiling with microbiome analysis in Indian populations are needed to validate biomarker utility and support precision management of IBS.
SN - 1017-7825
SN - 1738-8872
ER -